ICM Val d'Aurelle
ICM Val d'Aurelle
Montpellier, France19 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | Breast Cancer Recurrent | Active, not recruiting | Phase 3 | 2026-09-03 | NCT03820830 | |
| Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-08-04 | NCT06476184 | |
| Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Enrolling by invitation | Phase 2 | 2026-08-03 | NCT06680596 | |
| Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-10 | NCT07637851 | |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-07-09 | NCT02319837 | |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-06-04 | NCT04954820 | |
| Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-05-20 | NCT03870919 | |
| Treatment Intensification With Temozolomide in Adults With a Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2026-03-30 | NCT03663725 | |
| National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, connective tissue neoplasm, desmoid tumor, fibroma, neoplasm | Active, not recruiting | Not applicable | 2026-03-30 | NCT02867033 | |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone disorder, bone sarcoma, connective tissue neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, sarcoma | Recruiting | Phase 2 | 2026-02-17 | NCT04698785 | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | Disease Attributes, Disease Progression, Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Pathologic Complete Response, Pathologic Processes, Pathological Conditions, Signs and Symptoms, angiosarcoma, bone disorder, bone sarcoma, chondrosarcoma, connective tissue neoplasm, histiocytoma, leiomyosarcoma, musculoskeletal system disorder, myomatous neoplasm, neoplasm, osteosarcoma, sarcoma, undifferentiated pleomorphic sarcoma, vascular cancer | Recruiting | Not applicable | 2026-02-17 | NCT04055220 | |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2025-12-04 | NCT05201547 | |
| Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT | ovarian small cell carcinoma | Recruiting | Phase 2 | 2025-11-28 | NCT04602377 | |
| Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2025-09-04 | NCT06415266 | |
| Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-08-20 | NCT05625087 | |
| Development of a Clinical and Biological Database in Rectum Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Recruiting | Not applicable | 2025-02-13 | NCT04006951 | |
| Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, kidney cancer, kidney disorder, kidney failure, neoplasm, urinary system disorder | Recruiting | Not applicable | 2025-02-12 | NCT04823923 | |
| Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2025-02-12 | NCT04356209 | |
| Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence | Breast Cancer Female | Active, not recruiting | Not applicable | 2024-04-09 | NCT03127995 |